Abstract:Acute liver failure (ALF) is a serious inflammatory disorder with high mortality rates, which poses a significant threat to human health. The IL-33/ST2 signal is a crucial regulator in inflammation responses associated with lipopolysaccharide (LPS)-induced macrophages. The IL-17A signaling pathway promotes the release of chemokines and inflammatory cytokines, recruiting neutrophils and T cells under LPS stimulation, thus facilitating inflammatory responses. Here, the potential therapeutic benefits of neutralizing the IL-17A signal and modulating the IL-33/ST2 signal in ALF were investigated. A novel dual-functional fusion protein, anti-IL-17A-sST2, was constructed, which displayed high purity and biological activities. The administration of anti-IL-17A-sST2 resulted in significant anti-inflammatory benefits in ALF mice, amelioration of hepatocyte necrosis and interstitial congestion, and reduction in TNF-α and IL-6. Furthermore, anti-IL-17A-sST2 injection downregulated the expression of TLR4 and NLRP3 as well as important molecules such as MyD88, caspase-1, and IL-1β. The results suggest that anti-IL-17A-sST2 reduced the secretion of inflammatory factors, attenuated the inflammatory response, and protected hepatic function by regulating the TLR4/MyD88 pathway and inhibiting the NLRP3 inflammasome, providing a new therapeutic approach for ALF.

What problem does this paper attempt to address?

The problem this paper attempts to address is the high mortality rate of acute liver failure (ALF) and the lack of effective treatments. Specifically, the paper explores the therapeutic potential of a novel bifunctional fusion protein (anti-IL-17A-sST2) in ALF, aiming to alleviate inflammatory responses and protect liver function by modulating the TLR4/MyD88 pathway and NLRP3 inflammasome activation. ### Background - **Acute Liver Failure (ALF)**: This is a severe inflammatory disease usually caused by sudden liver dysfunction, characterized by massive hepatocyte death and excessive inflammatory response. The main causes include viral infections and drug-induced hepatotoxicity. - **Current Treatment Limitations**: Existing treatments such as hepatoprotective drugs, microecological regulation therapy, and hormone therapy are ineffective, often necessitating emergency liver transplantation. ### Research Objectives - **Exploring New Therapeutic Strategies**: By constructing a novel bifunctional fusion protein (anti-IL-17A-sST2), which simultaneously neutralizes IL-17A signaling and regulates IL-33/ST2 signaling, to reduce inflammatory responses and protect liver function in ALF. - **Mechanism Study**: To evaluate the regulatory effects of this fusion protein on the TLR4/MyD88 pathway and NLRP3 inflammasome activation, thereby reducing the secretion of inflammatory factors and inhibiting inflammatory responses. ### Main Findings - **Construction and Characterization of the Fusion Protein**: Successfully constructed a high-purity and biologically active anti-IL-17A-sST2 fusion protein. - **In Vivo Experimental Results**: - **Alleviation of Liver Injury**: anti-IL-17A-sST2 significantly improved hepatocyte necrosis and stromal congestion in LPS/D-GalN-induced ALF mice. - **Reduction of Inflammatory Factors**: Significantly reduced levels of TNF-α and IL-6. - **Regulation of TLR4/MyD88 Pathway**: Downregulated the expression of TLR4 and MyD88. - **Inhibition of NLRP3 Inflammasome Activation**: Reduced the number of NLRP3-positive stained cells and downregulated the expression of NLRP3, caspase-1, and IL-1β. ### Conclusion - **Potential Therapeutic Value**: anti-IL-17A-sST2 significantly alleviates inflammatory responses and liver injury in ALF by modulating the TLR4/MyD88 pathway and inhibiting NLRP3 inflammasome activation, providing a new strategy for the treatment of ALF.

A Novel Bifunctional Fusion Protein (Anti-IL-17A-sST2) Protects against Acute Liver Failure, Modulating the TLR4/MyD88 Pathway and NLRP3 Inflammasome Activation

TAK-242 Ameliorates Hepatic Fibrosis by Regulating the Liver-Gut Axis

The Inhibition of Bruton Tyrosine Kinase Alleviates Acute Liver Failure via Downregulation of NLRP3 Inflammasome.

The effect of histone deacetylase inhibitor ACY1215 on the inflammatory response in mice with acute liver failure

SINGLE NUCLEOTIDE POLYMORPHISM IN IFN WAS ASSOCIATED WITH ACUTE REJECTION AFTER LIVER TRANSPLANTATION

Inflammasome Activation Involved in Early Inflammation Reaction after Liver Transplantation.

Tectorigenin Protects Against Experimental Fulminant Hepatic Failure by Regulating the TLR4/mitogen‐activated Protein Kinase and TLR4/nuclear Factor‐κb Pathways and Autophagy

A Novel TNF-α-Targeting Aptamer for TNF-α-Mediated Acute Lung Injury and Acute Liver Failure

Stim-3 Alleviates Liver Injury Via Regulation of the Immunity Microenvironment and Autophagy

Endotoxin tolerance ameliorates lipopolysaccharide/D-galactosamine-induced acute liver failure by negative regulation of the NF-κB/NLRP3 and activation of Nrf2/HO-1 via Sitr1

Augmenter of Liver Regeneration Ameliorates Ischemia-Reperfusion Injury in Steatotic Liver Via Inhibition of the TLR4/NF-κB Pathway.

Isolicoflavonol ameliorates acute liver injury via inhibiting NLRP3 inflammasome activation through boosting Nrf2 signaling in vitro and in vivo

HIF-1α inhibition in macrophages preserves acute liver failure by reducing IL-1β production

Human endoderm stem cells reverse inflammation-related acute liver failure through cystatin SN-mediated inhibition of interferon signaling

Mefunidone ameliorates acute liver failure in mice by inhibiting MKK4-JNK pathway

miRNA‐21 promotes the progression of acute liver failure via the KLF6/autophagy/IL‐23 signaling pathway

Bacillus amyloliquefaciens SC06 Attenuated Lipopolysaccharide-Induced acute liver injury by suppressing bile acid-associated NLRP3 inflammasome activation

Garlic-derived exosome-like nanovesicles as a hepatoprotective agent alleviating acute liver failure by inhibiting CCR2/CCR5 signaling and inflammation

Selective PPARδ Agonist GW501516 Protects Against LPS-Induced Macrophage Inflammation and Acute Liver Failure in Mice via Suppressing Inflammatory Mediators

Long-term expanded hepatic progenitor cells ameliorate D-GalN/LPS-induced acute liver failure through repolarizing M1 macrophage to M2-Like phenotype via activation of the IL-10/JAK2/STAT3 signaling pathway

Microrna-223 Acts As an Important Regulator to Kupffer Cells Activation at the Early Stage of Con A-Induced Acute Liver Failure Via Aim2 Signaling Pathway